Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis-to-treatment interval can be highly variable with...

Descripció completa

Dades bibliogràfiques

Autors principals:	Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-05-01
Col·lecció:	Journal of Hematology & Oncology
Matèries:	POD24 Non-POD24 Marginal zone lymphoma Overall survival
Accés en línia:	https://doi.org/10.1186/s13045-023-01448-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!